NCT00141713View on ClinicalTrials.gov

The Use of Etanercept (Enbrel®) in the Treatment of Acute Graft-Versus-Host Disease

PHASE2CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

October 31, 2003

Primary Completion Date

November 30, 2006

Study Completion Date

December 31, 2006

Conditions
Graft-Versus-Host Disease
Interventions
DRUG

Etanercept

Patients enrolled on the study will receive etanercept at 0.4 mg/kg per dose up to a maximum of 25 mg per dose subcutaneously twice a week. Etanercept must be initiated within 72 hours of starting solumedrol.

Trial Locations (1)

48109

The University of Michigan Comprehensive Cancer Center, Ann Arbor

All Listed Sponsors
lead

University of Michigan Rogel Cancer Center

OTHER

NCT00141713 - The Use of Etanercept (Enbrel®) in the Treatment of Acute Graft-Versus-Host Disease | Biotech Hunter | Biotech Hunter